QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 限定条件 内容类型：期刊论文    专题：中国医学科学院 北京协和医学院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial 期刊论文 2013, 卷号: 14, 期号: 8, 页码: 777-786 作者:  Wu, Yi-Long;  Lee, Jin Soo;  Thongprasert, Sumitra;  Yu, Chong-Jen;  Zhang, Li 收藏  |  浏览/下载：1/0  |  提交时间：2020/01/13 INTERCALATED ERLOTINIB WITH GEMCITABINE/PLATINUM IN THE FIRST-LINE TREATMENT OF CHINESE PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): SUBANALYSIS FROM THE FASTACT-2 STUDY 期刊论文 2012, 卷号: 7, 期号: 11, 页码: S456-S456 作者:  Wu, Yi-long;  Liao, Meilin;  Zhu, Yunzhong;  Zhou, Caicun;  Sun, Yan 收藏  |  浏览/下载：1/0  |  提交时间：2020/01/13 chemotherapy  first line  Erlotinib  NSCLC   SUBSET ANALYSES OF EAST ASIAN PATIENTS ENROLLED IN THE MISSION PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF SORAFENIB MONOTHERAPY IN PATIENTS WITH ADVANCED RELAPSED/REFRACTORY NSCLC OF PREDOMINANTLY NON-SQUAMOUS HISTOLOGY WHO 期刊论文 2012, 卷号: 7, 期号: 11, 页码: S458-S458 作者:  Mok, Tony S. K.;  Wu, Yi-long;  Zhou, Caicun;  Sun, Yan;  Zhang, Li 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/13 NSCLC  sorafenib  MISSION Trial  East Asian   A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II 期刊论文 2012, 卷号: 30, 期号: 15 作者:  Mok, Tony;  Wu, Yi Long;  Thongprasert, Sumitra;  Yu, Chong-Jen;  Zhang, Li 收藏  |  浏览/下载：1/0  |  提交时间：2020/01/13 Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China 期刊论文 2012, 卷号: 8, 期号: 3, 页码: 232-243 作者:  Wu, Yi-Long;  Chu, Da-Tong;  Han, Baohui;  Liu, Xuyi;  Zhang, Li 收藏  |  浏览/下载：1/0  |  提交时间：2020/01/13 epidermal growth factor receptor (EGFR)  gefitinib  non-small-cell lung cancer